THE HALFAX HEIMDALL AUGUR

US launches Germany pharma pricing probe, raising threat of new tariffs Germany came under fresh US trade scrutiny on Thursday as the United States launched an investigation into the country's pharmaceutical pricing policies, a move that could pave the way for new tariffs. Washington said it would examine whether Germany's pricing practices unfairly underpay for innovative medicines and burden US commerce under Section 301 trade authorities.

Eyal Yakoby @EYakoby BREAKING: The Trump administration has launched a Section 301 investigation into Germany over drug pricing, arguing Berlin's policies force Americans to subsidize pharmaceutical innovation for the rest of the World. x.com/EYakoby/stat...

US starts Section 301 probe of Germany over pharmaceuticals US starts Section 301 probe of Germany over pharmaceuticals US launches Section 301 tariff probe into Germany over underpayment for innovative drugs, escalating trade tensions but leaving room for negotiation. By Bloomberg June 19, 2026, 7:56:20 AM IST (Published) 2 Min Read The US has launched a fresh tariff investigation into Germany over what it called persistent underpayment for innovative pharmaceutical products, setting the stage for levies on its goods in retaliation. US President Donald Trump has made clear that American patients should not be shouldering a disproportionate share of global pharmaceutical research and development, US Trade Representative Jamieson Greer said in a statement released on Thursday (June 18) night. “I am particularly concerned with news that Germany is fast-tracking legislation that would further reduce its spending on innovative pharmaceuticals. This is a serious step backwards at a time when our trading partners need to step up and start paying their fair share to fund innovative pharmaceutical research and development,” Greer added. The investigation is being carried out under a legal…

Why is the US targeting Germany's drug industry? A new trade probe is reigniting a long-running clash over who should pay for medical innovation. Washington argues Germans benefit from lower prices while US patients shoulder a disproportionate share of the costs.

USTR Announces Initiation of Section 301 Investigation of Germany's ... WASHINGTON — Today, U.S. Trade Representative Jamieson Greer initiated an investigation under Section 301 of the Trade Act of 1974 against Germany. This investigation will seek to determine whether persistent underpayment for innovative pharmaceutical products by Germany is unreasonable or discriminatory and burdens or restricts U.S. commerce. This investigation follows months of meaningful discussions with our German partners in an effort to resolve this issue. “President Trump has made clear that American patients should not be shouldering a disproportionate share of global pharmaceutical research and development,” said Ambassador Greer . “I am particularly concerned with news that Germany is fast-tracking legislation that would further reduce its spending on innovative pharmaceuticals. This is a serious step backwards at a time when our trading partners need to step up and start paying their fair share to fund innovative pharmaceutical research and development. We believe that the United States and Germany can find a path forward that expands access to the most innovative drugs for the German people while e…

US launches Section 301 probe into Germany over drug pricing Published byGlobal Banking & Finance Review Posted on June 19, 2026 · Last updated: June 19, 2026 By Jasper Ward WASHINGTON, June 18 (Reuters) - The U.S. has launched a trade investigation into a German plan to lower its spending on pharmaceutical products, to see whether it is unreasonable or discriminatory, U.S. Trade Representative Jamieson Greer said on Thursday. The probe comes under Section 301 of the Trade Act of 1974, Greer said, adding that his office will open a docket for submission of written comments on June 25 and its Section 301 Committee will hold a public hearing on the probe in September. "I am particularly concerned with news that Germany is fast-tracking legislation that would further reduce its spending on innovative pharmaceuticals," Greer said. The German Embassy in Washington did not immediately respond to a request for comment. The investigation, the sort of which Washington has already launched into dozens of other countries, comes after the German Ministry of Health unveiled plans in April for a ​wide-ranging overhaul of the country's statutory healthcare system to reduce a looming ‌fun…

US launches Section 301 probe into Germany over drug pricing | Business US launches Section 301 probe into Germany over drug pricing The US has launched an investigation under Section 301 of the Trade Act of 1974 against Germany over alleged underpayment for innovative pharmaceutical products. Reuters | The United States Has Initiated An Investigation Under Section Of The Trade Act Of Against Germany | Updated: 19-06-2026 05:47 IST | Created: 19-06-2026 05:47 IST Jamieson Greer Country: United States SHARE ​The ‌United States ​has initiated an ‌investigation under Section 301 of the ‌Trade Act of 1974 ‌against Germany, U.S. Trade Representative ⁠Jamieson ​Greer said ⁠on Thursday. The investigation ⁠will seek to ​determine whether persistent underpayment ⁠for innovative pharmaceutical ⁠products ​by Germany is unreasonable or ⁠discriminatory, the USTR ⁠said. POST / READ COMMENTS

'Ripping off the US': Why is US targeting Germany's drug industry? A new trade probe is reigniting a long-running clash over who should pay for medical innovation. Washington argues Germans benefit from lower prices while US patients shoulder a disproportionate share of the costs. In the world according to Donald Trump, every nation on the face of the earth is "ripping off" the United States — that goes for pharmaceuticals, too, especially those from Germany. Now, the Trump administration is targeting Germany with an investigation. Washington says it wants to find out if US patients and businesses are being forced to pay disproportionately higher prices for the research and development of top-tier pharmaceuticals so that German patients can pay less. Watch|As Putin's threat looms, this NATO nation's biggest €3 billion naval project falls apart? | Germany The inquiry, scheduled to wrap up in September, is based on Section 301 of the Trade Act of 1974 and could ultimately lead to new US tariffs. An old fight over different pricing rules The conflict touches on a core aspect of health policy. Germany regulates drug prices through its public health insurance system in order to kee…

Germany Drug Pricing US Section 301 Trade Probe Pharma Tariffs >> >> >> HEALTHCARE The United States has launched a trade investigation into Germany's pharmaceutical pricing policies, accusing Berlin of "persistent underpayment”. The Silicon Review asks: is Washington defending American patients or American drug company profits? The United States has opened a Section 301 trade investigation into Germanyover drug pricing. U.S. Trade Representative Jamieson Greer announced the probe on June 18, accusing Germany of "persistent underpayment for innovative pharmaceutical products" and "unreasonable" pricing practices. This comes afterGermany's Health Ministry announced in April a sweeping reform plan to plug a €20 billion ($23 billion) funding gapin its statutory healthcare system. The proposal introduced higher pharmaceutical discounts and cost-saving measures. A German cabinet source told Reuters this week that the plans were being withdrawn after sharp opposition from the pharmaceutical industry. "President Trump has made clear that American patients should not be shouldering a disproportionate share of global pharmaceutical research and development," Greer said in a statemen…

U.S. Initiates Trade Probe Against Germany Over 'Persistent ... U.S. Initiates Trade Probe Against Germany Over 'Persistent Underpayment' for Innovative Drugs News June 19, 2026 WASHINGTON D.C. - The United States has launched a formal trade investigation into Germany's pharmaceutical pricing practices, alleging that the European nation's policies constitute a "persistent underpayment" for innovative drugs. This probe, initiated on June 18, 2026, by U.S. Trade Representative Jamieson Greer under Section 301 of the Trade Act of 1974, marks a significant escalation in ongoing tensions over global drug pricing and the funding of pharmaceutical research and development. The move highlights deep-seated disagreements between two major economic allies regarding who should bear the costs of medical innovation. The Core of the Dispute: Funding Global Innovation At the heart of the U.S. investigation is the assertion that Germany's drug pricing policies are unreasonable, discriminatory, and unfairly burden or restrict U.S. commerce. American officials contend that these practices force U.S. patients to shoulder a disproportionately large share of global pharmaceutical research and developme…

US probes Germany's 'persistent underpayment' for drugs The US Trade Representative said a new probe would determine if Germany was a underpaying for pharmaceuticals.

U.S. opens tariff probe targeting Germany's drug pricing policies In this article The U.S. has launched an investigation into Germany's pharma policies over what it referred to as "persistent underpayment" for medicines as the European country looks to limit spiraling healthcare costs, including spending on drugs. "President Trump has made clear that American patients should not be shouldering a disproportionate share of global pharmaceutical research and development," said U.S. Trade Representative Jamieson Greerin a statement lateThursday. "I am particularly concerned with news that Germany is fast-tracking legislation that would further reduce its spending on innovative pharmaceuticals," he said, calling it "a serious step backwards." In April, Germany proposed overhauling its health insurance system to reduce pressure on public finances, amid increased health spending. It introduced a range of cost-saving measures, including higher discounts for insurance funds from the pharma industry, prompting numerousdrugmakers to warnthat they might withdraw or delay new medicines in the country. The draft legislation is currently going through parliamentary processes. Chancellor F…

US Starts Section 301 Probe of Germany Over Pharmaceuticals US Trade Representative Jamieson Greer initiated an investigation under Section 301 of the Trade Act of 1974 against Germany, according to a statement . Investigation will seek to determine whether “persistent underpayment for innovative pharmaceutical products by Germany is unreasonable or discriminatory and burdens or restricts U.S. commerce” Investigation follows months of “meaningful discussions with our German partners in an effort to resolve this issue” “I am particularly concerned with news that Germany is fast-tracking legislation that would further reduce its spending on innovative pharmaceuticals,” Greer says in statement NOTE: Merz’s Healthcare Overhaul Faces Resistance in German States © 2026 ... Learn more about Bloomberg Law or Log In to keep reading: See Breaking News in Context Bloomberg Law provides trusted coverage of current events enhanced with legal analysis. Learn more Already a subscriber? Log in to keep reading or access research tools and resources. Log In